

Special Issue

Molecular Targets to Enhance the Radiation Effect and Overcome Radiation Resistance in Cancer

Message from the Guest Editor

Dear colleagues This Special Issue on "Molecular Targets to Enhance the Radiation Effect and Overcome Radiation Resistance in Cancer" will focus on radiation resistance and overcoming it via molecular targeting as well as enhancing the radiation effect through pharmacological molecular interventions. Moreover, the synergistic effects of radiation and immunotherapy and the timing of radiation related to immunotherapy will be addressed. The interaction between novel molecular targets and radiation is also of significant relevance. The abscopal effect and the biology related to this phenomenon, post-radiation molecular changes, and radioligand therapy are currently large areas of interest in overcoming radioresistance and enhancing radiotherapeutic effects, where sub-areas in these fields have not been fully elucidated. With radiation therapy being a cornerstone of anticancer therapy, optimizing and enhancing therapeutic outcomes is vital, and progress in this area will serve a critical unmet need.

Guest Editor

Prof. Dr. Amichay Meirovitz

Soroka—Clalit & Ben Gurion University Medical Center, POB 151, Beer Sheva 8410101, Israel

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/165176

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).